Acclaro Medical Introduces AuraLux™ Fiber Laser: the Total Solution for Skin Health and Timeless Youth for All Aesthetic Providers and Patients
~ Next-Generation AuraLux Innovates Cold Fiber Laser Technology for Physician and MedSpa Practices Seeking Pioneering Preventative and Rejuvenation Treatments with Superior Safety, Less Discomfort and Minimal Downtime While Offering Practice Growth Opportunities
SMITHFIELD, R.I., April 10, 2025 /PRNewswire/ -- Acclaro Medical today announced the launch of AuraLux™ cold fiber laser, an evolution of its successful 2910 nm laser technology, specifically developed as an exclusive treatment solution for total skin health and timeless youth across all aesthetic practices and patient demographics. AuraLux will be unveiled at The Medical Spa Show to be held at the Wynn Las Vegas on April 10-13, 2025, and hosted by the American MedSpa Association, a leading multi-faceted national organization for the medical spa industry.
Capitalizing on Acclaro's winning UltraClear® cold ablative fiber laser, AuraLux is designed to prevent and correct the signs of skin aging using advanced engineering that produces a comfortable procedure to improve skin appearance with outstanding efficacy. AuraLux's CoolPulse™ technology automatically blends cold ablation and adjustable coagulation to precisely deliver the energy in the same channel for optimal results that minimize pain and downtime on all skin types. This approach triggers skin to restructure, produce new skin cells and initiate collagen remodeling for improvement of numerous skin conditions, including pre-aging flaws, fine lines, unwanted pigmentation, poor texture and scarring. With presets to ensure safety, AuraLux addresses every dimension of skin health, creating a curated treatment solution as a standalone procedure or integrated with other aesthetic treatments.
"AuraLux embodies the benefits of our flagship 2910 nm fiber laser platform, including the advantages of our CoolPulse technology and clinical versatility, to give providers and their patients safe and effective preventative and age-revitalizing treatments for comprehensive skin health," said Shlomo Assa, Co-Founder and President of Acclaro Medical. "We know that laser treatments can be intimidating. The introduction of AuraLux Fiber Laser helps ensure widespread accessibility to transformative laser experiences with glowing outcomes that enhance appearance and empower patient confidence."
AuraLux overcomes barriers to laser treatments such as pain, downtime and safety concerns, with four customizable modalities. These treatments accurately affect all skin layers, making it easier and more approachable for first timers as well as seasoned veterans:
3DMIRACL® targets the stratum corneum in a 10 to 15-minute prejuvenation treatment with improved surface texture and tone without the need for numbing cream in most cases
REFRESH targets the stratum corneum to the epidermis to correct fine lines, moderate to mild sun damage, age spots and discoloration for healthy, radiant skin
RENEW targets the dermis to produce deep collagen remodeling1 that improves scarring, addresses wrinkles and enhances overall skin health
GLIDE is a novel in-motion technique that delivers randomized pulses to the treatment area, reducing the risk of hyperpigmentation and offering quicker treatments for large areas
"The AuraLux Fiber Laser ushers in timeless youth and skin health while elevating our treatment outcomes and business economics," said Scott Gerrish, MD, a leading expert in regenerative medesthetics with practices in Vienna, VA and Scottdale, AZ. "Unlike other energy devices, AuraLux is engineered to minimize pain and downtime while aiming to achieve smooth skin and a glowing complexion for our patients."
Catering to the increasing popularity of gentle yet effective non-invasive treatments, AuraLux unlocks a significant new revenue stream, driving practice growth, repeat visits and referrals. This makes AuraLux the ideal investment for new and existing aesthetic practices building a thriving laser practice with cost-effective technology that can replace multiple devices with one FDA-cleared system. Its sleek and luxurious 'tabletop' design, featuring an intuitive GUI and built-in safety settings, integrates seamlessly into all practice types.
About AuraLux™AuraLux is a breakthrough in cold fiber laser technology, offering a safe, virtually painless and effective solution for total skin health. Its chic design and user-friendly interface make it easy to use on all skin types, providing one of the quickest ROIs ever experienced from a laser purchase. With its minimal downtime, speedy recovery and high accessibility, AuraLux is a game-changer that leaves patients with a radiant glow, timeless youth and boosted confidence. For more information, log on to auralux.com.
About Acclaro MedicalFounded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market groundbreaking solutions to address today's unmet medical, aesthetic and surgical practice needs. Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry. Its flagship UltraClear 2910nm Fiber Laser featuring proprietary 3DIntelliPulse™, 3DMIRACL® and Laser Coring™ skin rejuvenation treatments are valued for delivering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit http://www.ultraclearlaser.com.
Media Contact:Nadine Tosk,Nadine Tosk Communicationsnadinepr@gmail.com; 504.453.8344
1 per mechanism of action
View original content to download multimedia:https://www.prnewswire.com/news-releases/acclaro-medical-introduces-auralux-fiber-laser-the-total-solution-for-skin-health-and-timeless-youth-for-all-aesthetic-providers-and-patients-302426001.html
SOURCE Acclaro Medical Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Business Upturn
a day ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
a day ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
